P2Y12抑制剂-话题@MedSci

#P2Y12抑制剂#

19篇内容 | 790人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1442739, encodeId=35861442e394e, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！, objectType=article, longId=301028, objectId=7a613010288a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a613010288a, replyNumber=0, likeNumber=36, createdTime=2022-03-19, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a613010288a, moduleTitle=EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a613010288a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442738, encodeId=d9801442e3864, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益, objectType=article, longId=294328, objectId=43cc29432875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43cc29432875, replyNumber=0, likeNumber=39, createdTime=2022-01-21, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43cc29432875, moduleTitle=JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43cc29432875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442737, encodeId=205a1442e3720, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=Heart：阿司匹林与P2Y12抑制剂联合抗凝治疗对房颤的疗效分析, objectType=article, longId=214509, objectId=d98d214509a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d98d214509a2, replyNumber=0, likeNumber=39, createdTime=2021-07-22, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d98d214509a2, moduleTitle=Heart：阿司匹林与P2Y12抑制剂联合抗凝治疗对房颤的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d98d214509a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442736, encodeId=22de1442e3662, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大, objectType=article, longId=212913, objectId=5ce1212913f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ce1212913f0, replyNumber=0, likeNumber=45, createdTime=2021-06-20, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ce1212913f0, moduleTitle=BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ce1212913f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442735, encodeId=41de1442e35d2, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=Circulation：三种P2Y12抑制剂、四种服用方式用于ST段抬高型心肌梗死患者的疗效, objectType=article, longId=198976, objectId=9d641989e681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d641989e681, replyNumber=0, likeNumber=37, createdTime=2020-08-09, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d641989e681, moduleTitle=Circulation：三种P2Y12抑制剂、四种服用方式用于ST段抬高型心肌梗死患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d641989e681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442734, encodeId=c7361442e344d, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=Circulation：三种口服P2Y12抑制剂治疗急性冠脉综合征的疗效对比, objectType=article, longId=197924, objectId=487a19e924cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=487a19e924cf, replyNumber=0, likeNumber=43, createdTime=2020-07-24, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=487a19e924cf, moduleTitle=Circulation：三种口服P2Y12抑制剂治疗急性冠脉综合征的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=487a19e924cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442733, encodeId=0b751442e3341, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=Lancet：P2Y12抑制剂能够挑战阿司匹林动脉粥样硬化二级预防的地位吗？, objectType=article, longId=196863, objectId=d648196863d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d648196863d0, replyNumber=0, likeNumber=43, createdTime=2020-07-02, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d648196863d0, moduleTitle=Lancet：P2Y12抑制剂能够挑战阿司匹林动脉粥样硬化二级预防的地位吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d648196863d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442732, encodeId=55ec1442e32b1, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=Lancet：P2Y12抑制剂 vs 阿司匹林用于脉粥样硬化患者二级预防, objectType=article, longId=193805, objectId=2d31193805d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d31193805d5, replyNumber=0, likeNumber=38, createdTime=2020-05-10, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d31193805d5, moduleTitle=Lancet：P2Y12抑制剂 vs 阿司匹林用于脉粥样硬化患者二级预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d31193805d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442731, encodeId=eccb1442e3185, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=EUR HEART J-CARD PHA：P2Y12抑制剂在急性冠脉综合征合并肾功能不全患者中的应用如何？, objectType=article, longId=187599, objectId=d44518e599f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d44518e599f3, replyNumber=0, likeNumber=32, createdTime=2020-02-08, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d44518e599f3, moduleTitle=EUR HEART J-CARD PHA：P2Y12抑制剂在急性冠脉综合征合并肾功能不全患者中的应用如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d44518e599f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442730, encodeId=71c71442e3002, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=EUR HEART J-CARD PHA：接受PCI治疗的心肌梗死患者接受无规划糖蛋白IIb/IIIa抑制剂的p2y12抑制剂患者的肝素抗凝程度与临床结果的关系, objectType=article, longId=187475, objectId=0c5518e475ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c5518e475ae, replyNumber=0, likeNumber=36, createdTime=2020-02-06, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c5518e475ae, moduleTitle=EUR HEART J-CARD PHA：接受PCI治疗的心肌梗死患者接受无规划糖蛋白IIb/IIIa抑制剂的p2y12抑制剂患者的肝素抗凝程度与临床结果的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c5518e475ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442729, encodeId=fb4a1442e29a0, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=NEJM：口服P2Y12抑制剂基因指导原则, objectType=article, longId=181908, objectId=d6d81819084b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6d81819084b, replyNumber=0, likeNumber=34, createdTime=2019-10-26, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6d81819084b, moduleTitle=NEJM：口服P2Y12抑制剂基因指导原则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6d81819084b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442728, encodeId=11d81442e28c6, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=NEJM：原发性PCI患者口服P2Y12抑制剂的基因导向策略, objectType=article, longId=178970, objectId=02321e8970bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02321e8970bd, replyNumber=0, likeNumber=32, createdTime=2019-09-07, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02321e8970bd, moduleTitle=NEJM：原发性PCI患者口服P2Y12抑制剂的基因导向策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02321e8970bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442727, encodeId=efc21442e2777, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=JAMA：P2Y12抑制剂单药治疗对PCI患者心血管事件的影响研究, objectType=article, longId=173295, objectId=7d9e1e32952a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d9e1e32952a, replyNumber=0, likeNumber=29, createdTime=2019-06-28, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d9e1e32952a, moduleTitle=JAMA：P2Y12抑制剂单药治疗对PCI患者心血管事件的影响研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d9e1e32952a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442726, encodeId=d4c31442e26b9, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=【尖锋档案】P2Y12抑制剂的转换, objectType=article, longId=133590, objectId=c8001335902c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8001335902c, replyNumber=0, likeNumber=26, createdTime=2018-03-28, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8001335902c, moduleTitle=【尖锋档案】P2Y12抑制剂的转换, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8001335902c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442725, encodeId=d6fa1442e25b6, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=Am Heart J：强效P2Y12抑制剂使ACS患者获益年龄不是问题, objectType=article, longId=127320, objectId=074b12e320a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=074b12e320a9, replyNumber=0, likeNumber=35, createdTime=2018-01-24, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=074b12e320a9, moduleTitle=Am Heart J：强效P2Y12抑制剂使ACS患者获益年龄不是问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=074b12e320a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442724, encodeId=53641442e245f, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=Circulation:转换血小板P2Y12抑制剂治疗的国际专家共识, objectType=article, longId=124756, objectId=eba3124e5682, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba3124e5682, replyNumber=0, likeNumber=28, createdTime=2017-12-28, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba3124e5682, moduleTitle=Circulation:转换血小板P2Y12抑制剂治疗的国际专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba3124e5682)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442723, encodeId=83031442e230d, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=【AHA2017】GEMINI-ACS-1研究：药物基因检测对P2Y12抑制剂方案转换影响甚微, objectType=article, longId=120661, objectId=dcc912066195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcc912066195, replyNumber=0, likeNumber=34, createdTime=2017-11-20, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcc912066195, moduleTitle=【AHA2017】GEMINI-ACS-1研究：药物基因检测对P2Y12抑制剂方案转换影响甚微, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcc912066195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442722, encodeId=3ca81442e221c, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=【AHA2017】真实世界数据挑战临床试验结果：新型P2Y12抑制剂真的优于氯吡格雷？, objectType=article, longId=120654, objectId=cd061206549f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd061206549f, replyNumber=0, likeNumber=37, createdTime=2017-11-20, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd061206549f, moduleTitle=【AHA2017】真实世界数据挑战临床试验结果：新型P2Y12抑制剂真的优于氯吡格雷？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd061206549f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442721, encodeId=59351442e21a0, content=<a href='/topic/show?id=687313616b4' target=_blank style='color:#2F92EE;'>#P2Y12抑制剂#</a>, objectTitle=Lancet：急性冠脉综合征临床显著出血：P2Y12抑制剂+利伐沙班vs阿司匹林, objectType=article, longId=99395, objectId=1a2d99395a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a2d99395a3, replyNumber=0, likeNumber=36, createdTime=2017-05-24, rootId=0, userName=luckyshitiancai_42705685, userId=ff014972968, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a2d99395a3, moduleTitle=Lancet：急性冠脉综合征临床显著出血：P2Y12抑制剂+利伐沙班vs阿司匹林, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a2d99395a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

P2Y12抑制剂

2020-05-29

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！

2022-03-19

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益

2022-01-21

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

Heart：阿司匹林与P2Y12抑制剂联合抗凝治疗对房颤的疗效分析

2021-07-22

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

BMJ：重磅！冠脉重建后DAPT治疗的核心地位被动摇，P2Y12抑制剂单药治疗或收益更大

2021-06-20

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

Circulation：三种P2Y12抑制剂、四种服用方式用于ST段抬高型心肌梗死患者的疗效

2020-08-09

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

Circulation：三种口服P2Y12抑制剂治疗急性冠脉综合征的疗效对比

2020-07-24

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

Lancet：P2Y12抑制剂能够挑战阿司匹林动脉粥样硬化二级预防的地位吗？

2020-07-02

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

Lancet：P2Y12抑制剂 vs 阿司匹林用于脉粥样硬化患者二级预防

2020-05-10

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

EUR HEART J-CARD PHA：P2Y12抑制剂在急性冠脉综合征合并肾功能不全患者中的应用如何？

2020-02-08

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

EUR HEART J-CARD PHA：接受PCI治疗的心肌梗死患者接受无规划糖蛋白IIb/IIIa抑制剂的p2y12抑制剂患者的肝素抗凝程度与临床结果的关系

2020-02-06

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

NEJM：口服P2Y12抑制剂基因指导原则

2019-10-26

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

NEJM：原发性PCI患者口服P2Y12抑制剂的基因导向策略

2019-09-07

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

JAMA：P2Y12抑制剂单药治疗对PCI患者心血管事件的影响研究

2019-06-28

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

【尖锋档案】P2Y12抑制剂的转换

2018-03-28

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

Am Heart J：强效P2Y12抑制剂使ACS患者获益年龄不是问题

2018-01-24

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

Circulation:转换血小板P2Y12抑制剂治疗的国际专家共识

2017-12-28

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

【AHA2017】GEMINI-ACS-1研究：药物基因检测对P2Y12抑制剂方案转换影响甚微

2017-11-20

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

【AHA2017】真实世界数据挑战临床试验结果：新型P2Y12抑制剂真的优于氯吡格雷？

2017-11-20

luckyshitiancai_42705685 (审核中...)

前往app查看评论内容

#P2Y12抑制剂#

Lancet：急性冠脉综合征临床显著出血：P2Y12抑制剂+利伐沙班vs阿司匹林

2017-05-24

科室
- - 订阅+
  - 更多科室
工具
服务